X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fulford India with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs AUROBINDO PHARMA - Comparison Results

FULFORD INDIA    Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA AUROBINDO PHARMA FULFORD INDIA/
AUROBINDO PHARMA
 
P/E (TTM) x 398.8 16.2 2,456.3% View Chart
P/BV x 6.2 4.1 152.1% View Chart
Dividend Yield % 0.1 0.4 22.2%  

Financials

 FULFORD INDIA   AUROBINDO PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
AUROBINDO PHARMA
Mar-17
FULFORD INDIA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs942895 105.3%   
Low Rs450622 72.3%   
Sales per share (Unadj.) Rs691.4254.6 271.6%  
Earnings per share (Unadj.) Rs11.539.3 29.2%  
Cash flow per share (Unadj.) Rs15.446.6 33.0%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.30.3 87.2%  
Book value per share (Unadj.) Rs380.0160.0 237.6%  
Shares outstanding (eoy) m3.90585.88 0.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.03.0 33.8%   
Avg P/E ratio x60.719.3 314.5%  
P/CF ratio (eoy) x45.316.3 278.3%  
Price / Book Value ratio x1.84.7 38.6%  
Dividend payout %17.46.4 274.2%   
Avg Mkt Cap Rs m2,714444,390 0.6%   
No. of employees `0000.414.0 3.2%   
Total wages/salary Rs m50517,678 2.9%   
Avg. sales/employee Rs Th6,073.010,667.8 56.9%   
Avg. wages/employee Rs Th1,137.41,264.3 90.0%   
Avg. net profit/employee Rs Th100.71,645.8 6.1%   
INCOME DATA
Net Sales Rs m2,696149,157 1.8%  
Other income Rs m1251,159 10.8%   
Total revenues Rs m2,822150,316 1.9%   
Gross profit Rs m-4634,343 -0.1%  
Depreciation Rs m154,276 0.4%   
Interest Rs m10667 1.4%   
Profit before tax Rs m5430,558 0.2%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m107,597 0.1%   
Profit after tax Rs m4523,012 0.2%  
Gross profit margin %-1.723.0 -7.5%  
Effective tax rate %17.724.9 71.1%   
Net profit margin %1.715.4 10.7%  
BALANCE SHEET DATA
Current assets Rs m1,73892,062 1.9%   
Current liabilities Rs m54566,223 0.8%   
Net working cap to sales %44.317.3 255.5%  
Current ratio x3.21.4 229.6%  
Inventory Days Days48106 45.7%  
Debtors Days Days468 6.4%  
Net fixed assets Rs m1262,919 0.0%   
Share capital Rs m39586 6.7%   
"Free" reserves Rs m1,44393,133 1.5%   
Net worth Rs m1,48293,719 1.6%   
Long term debt Rs m01,814 0.0%   
Total assets Rs m2,077162,494 1.3%  
Interest coverage x6.746.8 14.3%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.9 141.5%   
Return on assets %2.614.6 17.9%  
Return on equity %3.024.6 12.3%  
Return on capital %4.332.7 13.1%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1775,838 0.0%   
Fx outflow Rs m67330,224 2.2%   
Net fx Rs m-65645,613 -1.4%   
CASH FLOW
From Operations Rs m9032,786 0.3%  
From Investments Rs m105-17,870 -0.6%  
From Financial Activity Rs m-14-19,153 0.1%  
Net Cashflow Rs m181-4,239 -4.3%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 8.0 47.8%  
FIIs % 0.1 27.7 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.2 207.8%  
Shareholders   4,783 69,601 6.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare FULFORD INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 8-QTR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS